

## Solidarity II – COVID-19 Seroepidemiology Study

Notes from Meeting on 10 March 2020

### Introductions

2. Progress on developing an External Positive Control panel (10)(2e)
3. Update on sourcing antigen (10)(2e)
4. Feedback from questionnaire survey (10)(2e)
5. Follow-up actions

### Progress on developing an External Positive Control panel (10)(2e)

- While an international standard will take many months to develop, we can start in a progressive manner, first by producing an External Positive Control (end of April) and subsequently developing a Research Reagent (June/July) in a panel of high, medium and low samples.
- NISBC has received over 1 litre of plasma. Testing will be done by PHE Porton Down by (10)(2e) and his team as the commercial assays available to NISBC do not perform well.
- Collaborators who wish to use the External Positive Control should also consider sharing their data with NISBC to help them develop their validation panel.

### Update on sourcing antigen (10)(2e)

- The stabilized spike protein as described by Wrapp et al is apparently the most suitable antigen for EILISAs.
- Only small quantities of the stabilized spike are available from NIAID/BEI.
- Two other potential sources of larger quantities are BMGF/Nexalus (extra production would be needed) and CDC.

### Presentation by (10)(2e), St Petersburg Research Institute for Vaccines and Sera

- They are developing a panel of small volumes of sear from convalescent patients.
- The assay developed by the Insitute showed good detection of IgG and IgM.

### Feedback on Questionnaire to Solidarity II Collaborators

14 questionnaires have been submitted to date and highlights were briefly reviewed.

### Follow-up Actions

- Next Meeting, Friday 17 April, 2020